Abstract
We investigated the anatomical and behavioural effects of daily intraperitoneal injection of 25 microg/kg of LIF in the SOD1(G93A G1H) mouse model of familial ALS. We found some subtle beneficial behavioural changes in LIF treated mice. These included later onset of clinical disease in females as determined by clinical scoring; better grip strength in males; and delayed development of motor impairment in males as determined by the rotarod test. However, we found no significant rescue of motoneurons or prolongation of survival as a result of this systemic dose of LIF in these mice.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aging
-
Amyotrophic Lateral Sclerosis / genetics*
-
Amyotrophic Lateral Sclerosis / pathology
-
Amyotrophic Lateral Sclerosis / physiopathology
-
Amyotrophic Lateral Sclerosis / psychology*
-
Animals
-
Behavior, Animal / drug effects*
-
Disease Models, Animal
-
Female
-
Growth Inhibitors / administration & dosage*
-
Hand Strength
-
Humans
-
Injections, Intraperitoneal
-
Interleukin-6*
-
Leukemia Inhibitory Factor
-
Lymphokines / administration & dosage*
-
Male
-
Mice
-
Mice, Transgenic
-
Motor Activity
-
Mutation*
-
Sex Characteristics
-
Superoxide Dismutase / genetics*
-
Superoxide Dismutase-1
Substances
-
Growth Inhibitors
-
Interleukin-6
-
LIF protein, human
-
Leukemia Inhibitory Factor
-
Lif protein, mouse
-
Lymphokines
-
SOD1 protein, human
-
Sod1 protein, mouse
-
Superoxide Dismutase
-
Superoxide Dismutase-1